Panacea Biotec Ltd. benchmarking: Perfomance to industry peers

Financial

	Panacea Biotec	Novartis	Indoco Remedies
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	6.0 .	n/a	54.0 .
R&D as a % of Total Sales	9.86 %	n/a	5.7 %
Financials
5 yr Average ROE	36.5 %	8.0 %	8.94 %
5yr average Equity Multiplier	0.36	2.72	1.9
5yr Average Asset Turnover Ratio	0.41	0.18	0.88
5yr Avg Net Profit Margin	26.1 %	17.12 %	5.41 %
Price to Book	2.51	2.52	2.27
P/E	0.0	18.3	0.0
5yr Avg Cash Conversion Cycle	-170.26 Days	-23.33 Days	35.3 Days
Inventory Days	120.03 Days	44.27 Days	70.6 Days
Days Receivable	42.2 Days	38.18 Days	83.16 Days
Days Payable	325.14 Days	124.28 Days	111.01 Days
5yr Average Interest Coverage Ratio	2.7	65.43	7.53
5yr Avg ROCE	-2.79 %	5.91 %	13.6 %
5yr Avg Operating Profit Margin	-3.85 %	15.15 %	14.97 %
5 yr average Debt to Equity	-0.69	0.0	0.49
5yr CAGR Net Profit	-43.68 %	37.01 %	n/a
5yr Average Return on Assets	9.32 %	3.13 %	5.31 %
Shareholdings
Promoter Holding	72.48 %	70.68 %	58.9 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	-1.11 %	0.0	0.21 %
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.31 %

Business

	Panacea Biotec	Novartis	Indoco Remedies
Therapeutic Area Wise Break-Up - Domestic	Therapeutic Area Wise Break-Up - Domestic Anti - Diabetes 43.91 Gastro Intestinal 13.47 Pain Management 12.87 Anti-Neoplastics 8.18 Vitamins / Minerals / Nutrients 6.09 Respiratory Systems 5.39 Vaccines 5.39 Blood Related 2.99 Hormones 0.6 Cardiac 0 Urological 0 Dermatology 0 Gynaecology 0 Pain / Analgesics 0 Ophthal / Otologicals 0 Vitamins / Minerals / Nutrients 0 Anti-Infectives 0 Stomatologicals 0 Others 1.11	-	Therapeutic Area Wise Break-Up - Domestic Respiratory Systems 0 Vitamins / Minerals / Nutrients 9.07 Urology 8.44 Stomatologicals 13.47 Dermatology 5.05 Cardiac Science 3.12 Pain Management 3.41 Gynecology 1.17 Anti - Diabetes 0 Hormones 0 Anti-Neoplastics 0 Anti-Infective 15.18 Ophthalmology 5.88 Vaccines 0 Gastro Intestinal 18.13 Pain Management 0 Blood Related 0 Others 17.08
Product Wise Break-Up	Product Wise Break-Up Vaccines 64.34 Formulations 35.66 Research and Development 0 0 CRO, Analytical Services 0 API 0 Formulation 0	Product Wise Break-Up CRO, Analytical Services 0 Formulations 0 API 0 Formulation 0 Wholesale of pharmaceuticals and medical goods 100.0 Research and Development 0 Vaccines 0	Product Wise Break-Up CRO, Analytical Services 1.0 Formulations 0 Active Pharmaceutical Ingredient (API) 9.0 Formulations 90.0 0 Research and Development 0 Vaccines 0
Location Wise Break-Up	Location Wise Break-Up Rest of the World 86.09 India 13.91	Location Wise Break-Up India 100.0 Rest of the World 0	Location Wise Break-Up India 64.75 Rest of the World 35.25
Operating Profit Break-Up	Operating Profit Break-Up Others 100	-	-
Capex	Capex Vaccines 69.46 Formulations 30.54 Real estate 0	-	-
Brand Wise Break-Up	Brand Wise Break-Up PanGraf 21.0 Glizid Family 19.0 Sitcom Family 10.0 Mycept & Mycept 5.0 Livoluk Family 4.0 Panimun Bioral 4.0 PacliAll 1.0 Thank OD Family 0 Nimulid Family 0 Others 36.0	-	-
Asset Break-Up	Asset Break-Up Vaccines 69.42 Formulations 30.58 Real Estate 0	-	-

Panacea Biotec Ltd.

Panacea Biotec Ltd.

Financial

Business

SIGN UP FOR FREE